Anlotinib + Benmelstobart vs Surgery for Patients With Localized Renal Cell Carcinoma Scheduled to Undergo Partial Nephrectomy

NCT07627464 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

144

Enrollment

OTHER

Sponsor class

Conditions

Renal Cell Carcinoma (RCC)

Interventions

DRUG: Anlotinib hydrochloride + Benmelstobart + Partial nephrectomy
PROCEDURE: Partial nephrectomy

Sponsor

Tianjin Medical University Cancer Institute and Hospital